EULAR_2025
14. marts 2025 2025-03-16 10:37EULAR_2025
Educational Visit 2025
We look forward to the upcoming Educational Visit 2025 (EV25) which will take place from the 30th March to 3rd April 2025 at the Danish Centre for Expertise in Rheumatology at the Danish Hospital for Rheumatic Diseases in Sønderborg, Denmark. This year's theme is "Reproductive health and family planning".
Programme
New perspectives on family planning
This educational event is designed specifically for early-career professionals who have begun to engage in research related to rheumatic diseases and reproductive health. The workshops aim to foster a deeper understanding and to cultivate advancements in this specialized area of study. It is a great pleasure to be able to welcome 30 participants from 18 different countries as well as some of the most world renowned international experts in the field, who will fill the days with exciting presentations and interactive workshops. The participants have different backgrounds – some are PhD students, professors, rheumatologists etc. What they all have in common is that they have an interest in the topic and the dedication to improve patient care.
We will collaborate
We place great emphasis on strengthening collaboration between research units both nationally and internationally to achieve the best results for our patients.
HYPATIA reseacrh study
The HYPTATIA study is an international research project investigating whether the drug hydroxychloroquine (HCQ) can improve pregnancy outcomes for women with antiphospholipid antibodies when added to standard treatment during pregnancy.
HYPTATIA is the first randomized controlled trial to examine the effect of HCQ in pregnant women with these antibodies. If the results show positive effects, many women – both in Denmark and around the world – could benefit from this treatment in the future.
The HYPTATIA study aims to include a total of 400 women, of whom 328 are expected to achieve a pregnancy.
How is the study conducted?
Participants will take the medication daily throughout their pregnancy and until delivery. A control group will receive a placebo tablet. Participants will be closely monitored with regular visits and blood tests, and some will be asked to donate tissue from their placentas for research purposes.
In Denmark, participants are being recruited from Rigshospitalet, Hvidovre University Hospital, Odense University Hospital, Aalborg University Hospital, Aarhus University Hospital, and the Danish Hospital for Rheumatic Diseases. Hospitals in England, Italy, Ireland, and Canada are also participating in the study.
Expectations for the study
The study is expected to be completed in 2027.
